![]() | Only 14 pages are availabe for public view |
Abstract Schizophrenia is a chronic remitting and disruptive mental disorder associated with significant abnormalities and progressive deterioration of a wide variety of cognitive,psychosocial,vocational, and behavioral functioning. The point prevalence of schizophrenia is about five per thousand in the population. The use of antipsychotics alone as the main treatment modality may be limited not only by their inability to tackle the frequently occurring negative symptoms and cognitive impairments but also by producing a wide variety of adverse effects in the internal body or organ functioning. Because of the complex health problems and wide range of abnormalities and impairments concerning schizophrenia, comprehensive and multimodal treatment approaches should be considered and tested in different combinations, with the goal of reducing patients’ illness episodes and symptoms, as well as improving their functioning and quality of life in the longer term. The current study was carried out to investigate the following:The possible beneficial effects of celecoxib and omega-3 fatty acids in an amphetamine- induced animal model of schizophrenia. The outcome of their combination with risperidone in terms of potentiating its antipsychotic action. To clarify the molecular mechanisms by which they exert their beneficial effects. |